Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;5(3):595-615.
doi: 10.2147/tcrm.s4595. Epub 2009 Aug 3.

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

Michael Neely  1 , Andrea Kovacs
Affiliations

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

Michael Neely et al. Ther Clin Risk Manag. 2009 Jun.

Abstract

Darunavir is currently the most recently approved HIV-1 protease inhibitor. It is approved for twice-daily dosing with ritonavir in treatment-experienced patients as young as 6 years of age and is available in numerous pill strengths. Emergence of darunavir-specific mutations is generally slow; therefore it can retain activity against viral strains that are resistant to other protease inhibitors, including tipranavir. Darunavir pharmacokinetics, clinical efficacy, resistance mutations and pharmacodynamics, and adverse effects are reviewed here. Substantial data support its use as a potent, well-tolerated option for salvage therapy in highly treatment-experienced children and adolescents.

Keywords: adolescent; child; darunavir; protease inhibitors; treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Joint United Nations Programme on HIV/AIDS. [Accessed April 29, 2009];Report on the global AIDS epidemic. 2008 http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_....
    1. Malhotra A, Gaur S, Whitley-Williams P, Loomis C, Petrova A. Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. AIDS Res Ther. 2007;4:15. - PMC - PubMed
    1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. [Accessed April 2, 2009];Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2009 February 23; http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
    1. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81(24):13845–13851. - PMC - PubMed
    1. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314–2321. - PMC - PubMed